

## Autoimmune Nodopathy / Chronic Inflammatory Demyelinating Polyneuropathy Antibody Panel (NF140, NF155, NF186, CNTN1, CASPR1)

Test Name	Autoimmune Nodopathy Antibody Screen (NF140, NF155, NF186 CNTN1, CASPR1)
Abbreviation	AN Ab panel; CIDP Ab panel
CPT code	N/A (research use only)
Methodology	Fixed cell-based assay
Intended Use	Diagnosis of Nodopathies
Test requirements	<p><u>Specimen Type:</u> Serum</p> <p><u>Minimum volume:</u> 0.5 mL</p> <p><u>Preferred volume:</u> 3 mL</p> <p><u>Rejection criteria:</u> grossly hemolytic, icteric, or lipemic. If the sample arrives at room temperature.</p>
Specimen collection	<ul style="list-style-type: none"> <li>No patient preparation required before collection.</li> <li>5 mL SST tube (gold-top). Spin tubes, aliquot serum, and ship on cold-packs same day</li> </ul>
Specimen stability	Up to 1 week refrigerated (2 - 8°C) -20°C for longer term storage – avoid subsequent freeze thaws
Test schedule	Once every two weeks
TAT	2 to 3 weeks
Reference range	N/A
Limitations	<ul style="list-style-type: none"> <li>This test was developed and its performance characteristics determined by BCNI. The test was performed in a DAP, CAP and CLIA certified laboratory and is intended for clinical purposes</li> <li>Please indicate if patients are on immunotherapy.</li> </ul>
References	<ul style="list-style-type: none"> <li>Querol L, Lleixà C. Novel immunological and therapeutic insights in Guillain-Barré syndrome and CIDP. <i>Neurother.</i> 2021 Oct;18(4):2222-35.</li> <li>Querol L, et al. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. <i>Nat Rev Neurol.</i> 2017 Sep;13(9):533-47.</li> <li>Frykman H., Kumar P. et al. PNS 2022, Miami USA</li> </ul>

\*Testing performed at BC Neuroimmunology